Role of advanced glycation end products (AGEs) and their receptor (RAGE) in the pathogenesis of diabetic microangiopathy.

Role of advanced glycation end products (AGEs) and their receptor (RAGE) in the pathogenesis of diabetic microangiopathy.
复制标题

DOI：
--
复制
发表时间：
2003
期刊：
International journal of clinical pharmacology research
影响因子：
--
通讯作者：
S. Yamagishi;M. Takeuchi;Y. Inagaki;Kei-ichiro Nakamura;T. Imaizumi
S. Yamagishi;M. Takeuchi;Y. Inagaki;Kei-ichiro Nakamura;T. Imaizumi
中科院分区：
其他
文献类型：
--
作者：
S. Yamagishi;M. Takeuchi;Y. Inagaki;Kei-ichiro Nakamura;T. Imaizumi

文献摘要

被引文献

相似文献

Diabetic vascular complication is a leading cause of acquired blindness, end-stage renal failure, a variety of neuropathies and accelerated atherosclerosis, which could account for disabilities and high mortality rates in patients with diabetes. Chronic hyperglycemia is essentially involved in the pathogenesis of diabetic micro- and macrovascular complications via various metabolic derangements. In this review, we discuss the molecular mechanisms of diabetic retinopathy and nephropathy, especially focusing on advanced glycation end products (AGEs) and their receptor (RAGE) system. Several types of AGE inhibitors and their therapeutic implications in diseases, including diabetic microangiopathy, will be discussed in the next review article.